Mukherjee D, Sen S
Department of Heart and Hypertension Research, Cleveland Clinic Foundation, OH 44195-5071.
J Mol Cell Cardiol. 1993 Feb;25(2):185-96. doi: 10.1006/jmcc.1993.1021.
The myocardium contains a fibrillar collagen matrix that consists primarily of type I and type III collagens. There is a marked alteration in the ratio and amount of collagen phenotypes in myocardial hypertrophy due to pressure overload. The purpose of the present study is (1) to study the effect of antihypertensive therapy on collagen phenotypes, if instituted before development of hypertension in spontaneously hypertensive rat (SHR), and continued into adult life and (2) to study the effects of dissociation of hypertension from hypertrophy, on collagen phenotypes in SHRs. The present study shows the effect of two antihypertensive drugs, hydralazine and captopril, on collagen phenotypes in SHRs. Both hydralazine and captopril effectively controlled blood pressure in SHRs, but only captopril regressed hypertrophy and corrected the altered distribution of myocardial collagen phenotypes I and III. Untreated SHRs had a collagen type I:III ratio of 10.19 +/- 0.27, compared with that of 6.41 +/- 0.30 in normotensive WKY (P < 0.001). Captopril-treated SHRs had a collagen type I:III ratio of 6.75 +/- 0.37, which did not differ significantly from that in normotensive WKY. Hydralazine-treated SHRs had a collagen I:III ratio of 10.07 +/- 0.39, which is similar to the ratio in untreated SHRs. In normotensive rats, neither captopril nor hydralazine significantly altered collagen content or the ratio of type I:III collagen. Thus captopril, an angiotensin converting enzyme inhibitor, not only regressed hypertrophy but also reversed the altered distribution of type I and type III collagen whereas hydralazine which effectively controlled blood pressure, did not regress hypertrophy and did not correct the altered distribution in collagen phenotypes. These studies suggest that alteration of collagen phenotypes during hypertensive hypertrophy is independent of blood pressure control and myocardial mass.
心肌含有一种纤维状胶原基质,主要由I型和III型胶原组成。由于压力超负荷,心肌肥大时胶原表型的比例和数量会发生显著改变。本研究的目的是:(1)研究抗高血压治疗对胶原表型的影响,若在自发性高血压大鼠(SHR)高血压发生前开始治疗,并持续至成年期;(2)研究高血压与肥大分离对SHR胶原表型的影响。本研究显示了两种抗高血压药物肼屈嗪和卡托普利对SHR胶原表型的影响。肼屈嗪和卡托普利均能有效控制SHR的血压,但只有卡托普利能使肥大消退,并纠正I型和III型心肌胶原表型分布的改变。未治疗的SHR的I型与III型胶原比例为10.19±0.27,而正常血压的WKY为6.41±0.30(P<0.001)。卡托普利治疗的SHR的I型与III型胶原比例为6.75±0.37,与正常血压的WKY无显著差异。肼屈嗪治疗的SHR的I型与III型胶原比例为10.07±0.39,与未治疗的SHR相似。在正常血压大鼠中,卡托普利和肼屈嗪均未显著改变胶原含量或I型与III型胶原的比例。因此,血管紧张素转换酶抑制剂卡托普利不仅能使肥大消退,还能逆转I型和III型胶原分布的改变,而能有效控制血压的肼屈嗪则不能使肥大消退,也不能纠正胶原表型分布的改变。这些研究表明,高血压性肥大期间胶原表型的改变与血压控制和心肌质量无关。